151 related articles for article (PubMed ID: 26716739)
1. [Molecular mechanisms of niclosamide antitumor activity].
Moskaleva EY; Perevozchikova VG; Zhirnik AS; Severin SE
Biomed Khim; 2015; 61(6):680-93. PubMed ID: 26716739
[TBL] [Abstract][Full Text] [Related]
2. Multi-targeted therapy of cancer by niclosamide: A new application for an old drug.
Li Y; Li PK; Roberts MJ; Arend RC; Samant RS; Buchsbaum DJ
Cancer Lett; 2014 Jul; 349(1):8-14. PubMed ID: 24732808
[TBL] [Abstract][Full Text] [Related]
3. Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells.
Pan JX; Ding K; Wang CY
Chin J Cancer; 2012 Apr; 31(4):178-84. PubMed ID: 22237038
[TBL] [Abstract][Full Text] [Related]
4. Identification of DK419, a potent inhibitor of Wnt/β-catenin signaling and colorectal cancer growth.
Wang J; Mook RA; Ren XR; Zhang Q; Jing G; Lu M; Spasojevic I; Lyerly HK; Hsu D; Chen W
Bioorg Med Chem; 2018 Nov; 26(20):5435-5442. PubMed ID: 30274939
[TBL] [Abstract][Full Text] [Related]
5. Effect of niclosamide on basal-like breast cancers.
Londoño-Joshi AI; Arend RC; Aristizabal L; Lu W; Samant RS; Metge BJ; Hidalgo B; Grizzle WE; Conner M; Forero-Torres A; Lobuglio AF; Li Y; Buchsbaum DJ
Mol Cancer Ther; 2014 Apr; 13(4):800-11. PubMed ID: 24552774
[TBL] [Abstract][Full Text] [Related]
6. Niclosamide-loaded polymeric micelles ameliorate hepatocellular carcinoma in vivo through targeting Wnt and Notch pathways.
Zeyada MS; Abdel-Rahman N; El-Karef A; Yahia S; El-Sherbiny IM; Eissa LA
Life Sci; 2020 Nov; 261():118458. PubMed ID: 32961231
[TBL] [Abstract][Full Text] [Related]
7. Niclosamide-induced Wnt signaling inhibition in colorectal cancer is mediated by autophagy.
Wang J; Ren XR; Piao H; Zhao S; Osada T; Premont RT; Mook RA; Morse MA; Lyerly HK; Chen W
Biochem J; 2019 Feb; 476(3):535-546. PubMed ID: 30635359
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer.
Arend RC; Londoño-Joshi AI; Samant RS; Li Y; Conner M; Hidalgo B; Alvarez RD; Landen CN; Straughn JM; Buchsbaum DJ
Gynecol Oncol; 2014 Jul; 134(1):112-20. PubMed ID: 24736023
[TBL] [Abstract][Full Text] [Related]
9. Injectable pegylated niclosamide (polyethylene glycol-modified niclosamide) for cancer therapy.
Ma R; Ma ZG; Gao JL; Tai Y; Li LJ; Zhu HB; Li L; Dong DL; Sun ZJ
J Biomed Mater Res A; 2020 Jan; 108(1):30-38. PubMed ID: 31433913
[TBL] [Abstract][Full Text] [Related]
10. Anticancer effects of niclosamide in human glioblastoma.
Wieland A; Trageser D; Gogolok S; Reinartz R; Höfer H; Keller M; Leinhaas A; Schelle R; Normann S; Klaas L; Waha A; Koch P; Fimmers R; Pietsch T; Yachnis AT; Pincus DW; Steindler DA; Brüstle O; Simon M; Glas M; Scheffler B
Clin Cancer Res; 2013 Aug; 19(15):4124-36. PubMed ID: 23908450
[TBL] [Abstract][Full Text] [Related]
11. Targeting Wnt/β-catenin by anthelmintic drug niclosamide overcomes paclitaxel resistance in esophageal cancer.
Wei W; Liu H; Yuan J; Yao Y
Fundam Clin Pharmacol; 2021 Feb; 35(1):165-173. PubMed ID: 32579788
[TBL] [Abstract][Full Text] [Related]
12. Niclosamide: Beyond an antihelminthic drug.
Chen W; Mook RA; Premont RT; Wang J
Cell Signal; 2018 Jan; 41():89-96. PubMed ID: 28389414
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity studies of Wnt/β-catenin inhibition in the Niclosamide chemotype: Identification of derivatives with improved drug exposure.
Mook RA; Wang J; Ren XR; Chen M; Spasojevic I; Barak LS; Lyerly HK; Chen W
Bioorg Med Chem; 2015 Sep; 23(17):5829-38. PubMed ID: 26272032
[TBL] [Abstract][Full Text] [Related]
14. New insights into niclosamide action: autophagy activation in colorectal cancer.
Newton PT
Biochem J; 2019 Mar; 476(5):779-781. PubMed ID: 30842311
[TBL] [Abstract][Full Text] [Related]
15. Niclosamide, a Drug with Many (Re)purposes.
Kadri H; Lambourne OA; Mehellou Y
ChemMedChem; 2018 Jun; 13(11):1088-1091. PubMed ID: 29603892
[TBL] [Abstract][Full Text] [Related]
16. Baicalein suppresses metastasis of breast cancer cells by inhibiting EMT via downregulation of SATB1 and Wnt/β-catenin pathway.
Ma X; Yan W; Dai Z; Gao X; Ma Y; Xu Q; Jiang J; Zhang S
Drug Des Devel Ther; 2016; 10():1419-41. PubMed ID: 27143851
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of a nanoformulated antihelminthic, niclosamide, in ovarian cancer.
Lin CK; Bai MY; Hu TM; Wang YC; Chao TK; Weng SJ; Huang RL; Su PH; Lai HC
Oncotarget; 2016 Feb; 7(8):8993-9006. PubMed ID: 26848771
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel triazole inhibitors of Wnt/β-catenin signaling based on the Niclosamide chemotype.
Mook RA; Wang J; Ren XR; Piao H; Lyerly HK; Chen W
Bioorg Med Chem Lett; 2019 Jan; 29(2):317-321. PubMed ID: 30551901
[TBL] [Abstract][Full Text] [Related]
19. Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species.
Jin Y; Lu Z; Ding K; Li J; Du X; Chen C; Sun X; Wu Y; Zhou J; Pan J
Cancer Res; 2010 Mar; 70(6):2516-27. PubMed ID: 20215516
[TBL] [Abstract][Full Text] [Related]
20. Taxifolin curbs NF-κB-mediated Wnt/β-catenin signaling via up-regulating Nrf2 pathway in experimental colon carcinogenesis.
Manigandan K; Manimaran D; Jayaraj RL; Elangovan N; Dhivya V; Kaphle A
Biochimie; 2015 Dec; 119():103-12. PubMed ID: 26482805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
